Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03745222
Title A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)
Acronym RATIONALE001
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene
Age Groups: senior | adult
Covered Countries USA | NZL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL

No variant requirements are available.